Aachen, Germany, 18 February 2026 Grünenthal launched at the current time that the first wholesome volunteers were enrolled in a Section I trial of its voltage-gated sodium channel (NaV) 1.8 inhibitor. The orally administered investigational medication objectives to give a non-opioid remedy option across a ramification of acute and chronic be troubled prerequisites. Burly results of the trial are anticipated within the 2nd half of 2026.
The Section I trial will private 70 wholesome volunteers and comprises a Single Ascending Dose and a A lot of Ascending Dose section. It objectives to evaluate the safety and tolerability profile and the pharmacokinetic traits of the investigational medication. Moreover, the trial will generate preliminary insights into the compound’s pharmacology by means of a cold-pressor check.
“Inhibition of NaV 1.8 offers an exciting opportunity to provide patients with urgently needed non-opioid pain therapies,” says Uli Brödl, Chief Scientific Officer, Grünenthal. “While we have seen the first medicine targeting NaV 1.8 receive FDA approval last year, we are committed to driving further innovation in this field where advanced assets may provide enhanced patient outcomes by blocking NaV 1.8 more comprehensively.”
About voltage-gated sodium channels (NaV)
There are a entire of 9 assorted NaV channels within the human body. The NaV 1.8 channel is a clinically and genetically validated be troubled purpose, because the channel plays a first-rate role in triggering excitatory signals in nociceptive neurons, which the human brain perceives as be troubled. Blocking the NaV 1.8 channel to suppress or cease its excitatory signalling will provide a first-rate analgesic enact across a ramification of chronic and acute be troubled prerequisites.
About Grünenthal
Grünenthal is a international chief in be troubled administration and connected diseases. As a science-based totally, totally integrated pharmaceutical company, we like a prolonged be aware document of bringing innovative therapies and cutting-edge applied sciences to patients worldwide. Our purpose is to alternate lives for the greater and innovation is our ardour. We level of curiosity all our actions and efforts on practising our imaginative and prescient of a World Freed from Anguish.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 international locations across Europe, Latin The US, and the U.S. Our merchandise would maybe be found in in approx. 100 international locations. In 2024, Grünenthal employed around 4,300 other folks and carried out revenues of 1.8 billion.
Extra data: https://www.grunenthal.com
Put together us on: LinkedIn: Grunenthal Physique of workers
Instagram: grunenthal
Click here for our Grünenthal Document 2024/2025
Contact Data
Maren Thurow
Grünenthal Physique of workers
—
Contact Us
